文献速递脑血管病

机械取栓治疗非轻型缺血性卒中的欧洲成本效益分析

Cost-Effectiveness of Mechanical Thrombectomy for Treatment of Nonminor Ischemic Stroke Across Europe.
PubMed 文献 · Stroke · 2021-01-11

该研究用Markov模型评估机械取栓相比标准治疗在32个欧洲国家非轻型缺血性卒中患者中的成本效益,时间跨度5年。

要点

  • 机械取栓在多数欧洲国家相比标准治疗更具成本效益且更省钱。
  • 仅保加利亚未显示成本效益,支持广泛推广取栓治疗。

核心结论

  • 机械取栓相比标准治疗在欧洲整体及绝大多数欧洲国家极可能具有成本效益。

研究设计与样本

  • 采用Markov模型,基于2017年各国发病率数据识别符合取栓的缺血性卒中患者,从社会视角评估5年时间跨度的成本效益。

主要发现

  • 机械取栓在三分之二的国家(21/32)比标准治疗更有效且更便宜。
  • 社会总成本节省17亿美元(15亿欧元,95%不确定性区间-1.2至3.6)。

临床怎么用

  • 支持在欧洲多数国家将机械取栓作为非轻型缺血性卒中的标准治疗策略。
  • 卫生决策者可参考该成本效益证据优化卒中救治资源配置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Mechanical thrombectomy (MT) has been recommended for the treatment of nonminor ischemic stroke by national and international guidelines, but cost-effectiveness evidence has been generated for only a few countries using heterogeneous evaluation methods. We estimate the cost-effectiveness of MT across 32 European countries. METHODS: A Markov model was developed to estimate the cost-effectiveness of MT compared with standard care over a 5-year time horizon. Patients with ischemic stroke eligible for MT were identified from 2017 country-specific incidence data. A societal perspective was adopted, including health, social, and informal care costs, and productivity losses. Model outcomes were expressed as quality-adjusted life years. Sensitivity analyses were conducted to test the robustness of findings. RESULTS: We identified 267 514 ischemic stroke cases that were eligible for MT treatment across 32 European countries. MT was found to be more effective and cheaper than standard care in two-thirds of the countries (21/32) and cost-effective in all but one country (Bulgaria). Across Europe, the intervention was estimated to produce over 101 327 additional quality-adjusted life years (95% uncertainty interval, 65 180-149 085) and cost savings of $981 million (€868 million, 95% uncertainty interval, -1544 to 2564) and of $1.7 billion (€1.5 billion, 95% uncertainty interval, -1.2 to 3.6) in health and social care and societal costs, respectively. CONCLUSIONS: MT is highly likely to be cost-effective compared with standard care across Europe as a whole and in the vast majority of European countries.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Candio P, Violato M, Leal J, et al. Cost-Effectiveness of Mechanical Thrombectomy for Treatment of Nonminor Ischemic Stroke Across Europe. Stroke. 2021. PMID: 33423511. doi:10.1161/STROKEAHA.120.031027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。